Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season
- PMID: 30141464
- PMCID: PMC6107316
- DOI: 10.15585/mmwr.rr6703a1
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season
Abstract
This report updates the 2017-18 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2017;66[No. RR-2]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. A licensed, recommended, and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV), and live attenuated influenza vaccine (LAIV) are expected to be available for the 2018-19 season. Standard-dose, unadjuvanted, inactivated influenza vaccines will be available in quadrivalent (IIV4) and trivalent (IIV3) formulations. Recombinant influenza vaccine (RIV4) and live attenuated influenza vaccine (LAIV4) will be available in quadrivalent formulations. High-dose inactivated influenza vaccine (HD-IIV3) and adjuvanted inactivated influenza vaccine (aIIV3) will be available in trivalent formulations.Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 25, 2017; February 21, 2018; and June 20, 2018. New and updated information in this report includes the following four items. First, vaccine viruses included in the 2018-19 U.S. trivalent influenza vaccines will be an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus, and a B/Colorado/06/2017-like virus (Victoria lineage). Quadrivalent influenza vaccines will contain these three viruses and an additional influenza B vaccine virus, a B/Phuket/3073/2013-like virus (Yamagata lineage). Second, recommendations for the use of LAIV4 (FluMist Quadrivalent) have been updated. Following two seasons (2016-17 and 2017-18) during which ACIP recommended that LAIV4 not be used, for the 2018-19 season, vaccination providers may choose to administer any licensed, age-appropriate influenza vaccine (IIV, RIV4, or LAIV4). LAIV4 is an option for those for whom it is appropriate. Third, persons with a history of egg allergy of any severity may receive any licensed, recommended, and age-appropriate influenza vaccine (IIV, RIV4, or LAIV4). Additional recommendations concerning vaccination of egg-allergic persons are discussed. Finally, information on recent licensures and labeling changes is discussed, including expansion of the age indication for Afluria Quadrivalent (IIV4) from ≥18 years to ≥5 years and expansion of the age indication for Fluarix Quadrivalent (IIV4), previously licensed for ≥3 years, to ≥6 months.This report focuses on the recommendations for use of vaccines for the prevention and control of influenza during the 2018-19 season in the United States. A Background Document containing further information and a brief summary of these recommendations are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html.These recommendations apply to U.S.-licensed influenza vaccines used within Food and Drug Administration-licensed indications. Updates and other information are available at CDC's influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check CDC's influenza website periodically for additional information.
Conflict of interest statement
Recommendations for routine use of vaccines in children, adolescents, and adults are developed by the Advisory Committee on Immunization Practices (ACIP). ACIP is chartered as a federal advisory committee to provide expert external advice and guidance to the Director of CDC on use of vaccines and related agents for the control of vaccine-preventable diseases in the civilian population of the United States. Recommendations for routine use of vaccines in children and adolescents are harmonized to the greatest extent possible with recommendations made by the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American College of Obstetricians and Gynecologists (ACOG). Recommendations for routine use of vaccines in adults are harmonized with recommendations of AAFP, ACOG, and the American College of Physicians (ACP). ACIP recommendations approved by the CDC Director become agency guidelines on the date published in the Morbidity and Mortality Weekly Report (MMWR). Additional information is available at https://www.cdc.gov/vaccines/acip. Emmanuel B. Walter reports grants from Novavax and Merck & Co, outside the submitted work. Other content experts and CDC planners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. This report includes discussion of the unlabeled use of influenza vaccines in the instance of vaccination of persons with a history of egg allergy. A history of severe allergic reaction to influenza vaccine or any of its components (including egg) is a labeled contraindication to receipt of most IIVs and LAIV. However, ACIP and CDC recommend that persons with egg allergy of any severity should receive any licensed, recommended, and age-appropriate influenza vaccine that is otherwise appropriate for their health status. Persons with a history of severe allergic reaction to egg should be vaccinated in an inpatient or outpatient medical setting (including, but not necessarily limited to, hospitals, clinics, health departments, and physician offices). Vaccine administration should be supervised by a health care provider who is able to recognize and manage severe allergic conditions. No postvaccination observation period is recommended specifically for egg-allergic persons. However, ACIP recommends that vaccine providers consider observing patients (seated or supine) for 15 minutes following administration of any vaccine to decrease the risk for injury should syncope occur.
Figures
Similar articles
-
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.MMWR Recomm Rep. 2017 Aug 25;66(2):1-20. doi: 10.15585/mmwr.rr6602a1. MMWR Recomm Rep. 2017. PMID: 28841201 Free PMC article.
-
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.MMWR Recomm Rep. 2021 Aug 27;70(5):1-28. doi: 10.15585/mmwr.rr7005a1. MMWR Recomm Rep. 2021. PMID: 34448800 Free PMC article.
-
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season.MMWR Recomm Rep. 2019 Aug 23;68(3):1-21. doi: 10.15585/mmwr.rr6803a1. MMWR Recomm Rep. 2019. PMID: 31441906 Free PMC article.
-
Recommendations for Prevention and Control of Influenza in Children, 2018-2019.Pediatrics. 2018 Oct;142(4):e20182367. doi: 10.1542/peds.2018-2367. Epub 2018 Sep 3. Pediatrics. 2018. PMID: 30177511 Review.
-
Updates on Influenza Vaccination in Children.Infect Dis Clin North Am. 2018 Mar;32(1):75-89. doi: 10.1016/j.idc.2017.11.005. Infect Dis Clin North Am. 2018. PMID: 29406978 Review.
Cited by
-
Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine.Nat Commun. 2023 Dec 5;14(1):8053. doi: 10.1038/s41467-023-43842-7. Nat Commun. 2023. PMID: 38052824 Free PMC article.
-
Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews.BMC Infect Dis. 2023 Aug 29;23(1):563. doi: 10.1186/s12879-023-08541-0. BMC Infect Dis. 2023. PMID: 37644401 Free PMC article. Review.
-
Active surveillance for adverse events of influenza vaccine safety in elderly cancer patients using self-controlled tree-temporal scan statistic analysis.Sci Rep. 2023 Aug 16;13(1):13346. doi: 10.1038/s41598-023-40091-y. Sci Rep. 2023. PMID: 37587127 Free PMC article.
-
Knowledge and Practice of Gynecologists About Tdap and Influenza Vaccination: A Cross-Sectional Study.Cureus. 2023 Jun 6;15(6):e40037. doi: 10.7759/cureus.40037. eCollection 2023 Jun. Cureus. 2023. PMID: 37425540 Free PMC article.
-
Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses.Front Bioeng Biotechnol. 2023 Jun 5;11:1097349. doi: 10.3389/fbioe.2023.1097349. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 37342504 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous